§ Since 2010, several provisions of the ACA have been put into pracGce and have potenGal to impact the access, pricing and uptake of various medical products and services
Background Objective
The Affordable Care Act (ACA) has introduced several major changes, which have had significant impact on pharmaceutical pricing, access and uptake in the United States. The objectives of this study were: § Review all major new changes due to ACA and develop a target list of adjustments for budget impact model (BIM) for US payers. § Assess likely impact of changes due to ACA on pricing and reimbursement.
The new pricing, access and coverage changes impacting the pharmaceutical and devices products were reviewed using the bill for ACA (H. R. 
Types of Rebates for Medicaid Discount Description

23.1%
Innovator Drugs
The greater of 23.1 % of the Average Manufacturer Price (AMP) per unit or the difference between the AMP and the best price per unit and adjusted by the Consumer Price Index-Urban (CPI-U) based on launch date and current quarter AMP.
17.1%
Blood Clotting Factors -the greater of 17.1 % of the AMP per unit or the difference between the AMP and the best price per unit and adjusted by the CPI-U based on launch date and current quarter AMP.
Drugs Approved by FDA Exclusively for Pediatric Indications -the larger of 17.1 % of the AMP per unit or the difference between the AMP and the best price per unit and adjusted by the CPI-U based on launch date and current quarter AMP
New Formula
Line Extensions -For a drug that is a new formulation (line extension) of a brand name drug that is an oral solid dosage form
13%
Non-innovator Drugs -13 % of the AMP per unit.
Summary Topic Implications
Increased Access
As of 01/2014 health insurance access has improved for a significantly smaller population than expected. States have opted out of Medicaid expansion and majority of signups for with new exchanges are previously insured patients
Part D Discounts
Phase out of donut hole is on-going as planned. As of 2014, beneficiaries are paying 47% of donut hole cost
Capped Deductibles
Capping of deductibles can potentially decrease patient share of the cost (especially for high cost specialty products)
ACOs
ACO rollout has been slower than expected. As of 01/2014 ~18million lives were covered under ACO programs (less than 7% of total population)
Medicaid Discounts
As per ACA drug manufactures have to provide discounts to Medicaid programs. CMS is now publishing NADAC files
Essential Health Benefits
As of 2014 plans are required to offer at least the coverage as per the EHB benchmark in each State. Significant variations exists in benchmark plans for pharmaceuticals
Awarded Two Platinum and One Bronze Medal by AMCP
